Singh, S., Z. Xiao, K. Bavisi, J. Roszik, B. D. Melendez, Z. Wang, M. J. Cantwell, R. E. Davis, G. Lizee, P. Hwu, S. S. Neelapu, W. W. Overwijk, and M. Singh. 2021. IL-1α mediates innate and acquired resistance to immunotherapy in melanoma. J. Immunol. 206: 1966–1975.
The Materials and Methods section erroneously omitted the manufacturer and clone of one of the Ab reagents used under the heading “Tumor induction, treatment, and monitoring.” The second sentence in this section reads “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10), anti-mouse Ly6G (1A8), anti–IL-1α (ALF-161), anti–IL-1β (B122), anti–IL-1R1 (JAMA-147), and/or 200 μg of anti–PD-L1 (10F.9G2) (all from Bio X Cell) or their isotype control Abs.” It should have read “Three days after tumor inoculation, mice were treated with i.p. injection of 200 μg of anti–CTLA-4 (9H10, Bio X Cell), anti-mouse Ly6G (1A8, Bio X Cell), anti–IL-1α (Flo1-2a, XBiotech), anti–IL-1β (B122, Bio X Cell), anti–IL-1R1 (JAMA-147, Bio X Cell), and/or 200 μg of anti–PD-L1 (10F.9G2, Bio X Cell) or their isotype control Abs.”